Neogenomics (NEO) Cash from Financing Activities (2010 - 2026)

Neogenomics (NEO) has reported Cash from Financing Activities for 17 consecutive years, with -$338000.0 the latest figure, recorded in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$338000.0, down 135.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$201.6 million (down 4317.93% YoY), and the FY2025 annual result was -$200.3 million, down 4410.98% from the prior year.
• Cash from Financing Activities was -$338000.0 for Q1 2026 at Neogenomics, down from $431000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $6.1 million in Q1 2022 and troughed at -$202.4 million in Q2 2025.
• Average Cash from Financing Activities over 5 years is -$10.6 million, with a median of $1.0 million recorded in 2022.
• Year-over-year, Cash from Financing Activities jumped 2971.88% in 2024 and tumbled 10396.69% in 2025.
• Over 5 years, Cash from Financing Activities stood at $1.8 million in 2022, then decreased by 29.52% to $1.3 million in 2023, then tumbled by 45.91% to $687000.0 in 2024, then tumbled by 37.26% to $431000.0 in 2025, then slumped by 178.42% to -$338000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$338000.0 in Q1 2026, $431000.0 in Q4 2025, and $765000.0 in Q3 2025.